Trials / Unknown
UnknownNCT06221423
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
A Single-center, Prospective Cohort Study of Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib Combined With TAS-102 | Fruquintinib Combined With TAS-102 |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2024-01-24
- Last updated
- 2024-01-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06221423. Inclusion in this directory is not an endorsement.